Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
The purpose of this study was to evaluate the efficacy and safety of docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Thirty-four patients with advanced NSCLC received docetaxel 75 mg/m2 (1-h intravenous infusion) every 3 weeks, with corticosteroid premedication...
Saved in:
Main Authors: | Thongprasert S., Cheewakriangkrai R., Napapan S. |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-0036985870&partnerID=40&md5=c9ee0ff44844ea8301aa32e0149fdcbf http://www.ncbi.nlm.nih.gov/pubmed/12678167 http://cmuir.cmu.ac.th/handle/6653943832/2100 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer
by: Sumitra Thongprasert, et al.
Published: (2018) -
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
by: Charoentum C., et al.
Published: (2014) -
Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
by: Chaiyut Charoentum, et al.
Published: (2018) -
Chemotherapy in non-small cell lung cancer: opportunities for advancement
by: Akhtari, M, et al.
Published: (2020) -
Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)